Peter Almond finished a trial for donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still ...

Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...

A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...